FEFiliz Başak Cengiz Ergin

Filiz Başak Cengiz Ergin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Filiz Başak Cengiz Ergin has a total of 61 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A Homozygous ALCAM–CBLB Deletion at 3q13.11‐q13.12 Defines a Candidate Novel Oculo‐Skeletal‐Immune Contiguous Gene Deletion Syndrome

    by Nilay Kan Menkü, Mehlika Meryem Sarı, Filiz Başak Ergin, Tuğçe İnal, Kazım Seçgen, Avniye Kübra Baskın, Rüştü Fikret Akata, Fatih Ezgü

    To our knowledge, we report the first combined homozygous deletion of ALCAM and CBLB at 3q13.11‐q13.12. The patient, a 14‐year‐old boy born to consanguineous parents, had a multisystem phenotype with severe congenital ocular and craniofacial anomalies, early‐onset osteoporosis, progressive scoliosis, growth failure, congenital heart defect, humoral immunodeficiency, and chronic inflammatory findings. SNP array identified a 2.5‐Mb homozygous deletion spanning ALCAM and CBLB , and expression studies confirmed complete absence of ALCAM and CBLB expression. Whole‐exome sequencing did not identify an alternative molecular diagnosis. The clinical presentation is likely attributable to combined ALCAM and CBLB loss. Previous animal‐model studies support interpretation of the individual phenotypic components by linking loss of these genes to craniofacial developmental abnormalities, skeletal findings, and immune dysregulation. We propose that this deletion may represent a candidate novel contiguous gene deletion syndrome. This case is the first human phenotype associated with complete ALCAM loss in a contiguous deletion and expands the clinical spectrum associated with disruption of ALCAM and CBLB .

  • Hemophagocytic Lymphohistiocytosis in a Patient With Gaucher Disease Having a Homozygous STXBP3 Variant

    by Mehlika Meryem Sarı, Nilay Kan Menkü, Aysel Yüce, Filiz Başak Ergin, Zühre Kaya, Ülker Koçak, İlYas Okur, Leyla Tümer, Fatih Süheyl Ezgü

  • Open Access

    Transcriptomic Profiling of Monozygotic Twins with Type 1 Gaucher Disease

    by Aslı İnci, Sümeyye Aydoğdu Demirel, Filiz Başak Cengiz Ergin, Gürsel Biberoğlu, İlyas Okur, Fatih Süheyl Ezgü, Leyla Tümer, Rıdvan Murat Öktem, Serap Dökmeci

    Background: Gaucher disease (GD) arises from pathogenic variants in the GBA1 gene and is known for its wide range of clinical presentations—a variability that genotype alone cannot adequately account for. Objective: This study aimed to explore transcriptomic factors that might help explain why two genetically identical twins with type 1 GD developed noticeably different clinical outcomes. Methods: We isolated peripheral blood mononuclear cells from both twins and two age-matched controls, then differentiated them into macrophages in vitro before conducting RNA sequencing. Gene expression differences were analyzed using established bioinformatics pipelines, and a subset of genes were subsequently assessed by quantitative real-time PCR (qRT-PCR) to confirm the sequencing findings. Results: Both twins shared a GD-associated transcriptional signature broadly reflecting immune activation and lysosomal stress. Interestingly, the twin who experienced systemic complications had a relative enrichment of interferon-responsive transcripts, while the less severely affected twin showed more pronounced suppression of small nucleolar RNA clusters. That said, neither difference held up after correcting for multiple comparisons, so these patterns are best viewed as exploratory trends rather than definitive findings. The qRT-PCR results lend partial support to this picture: stress- and immune-related genes (DDIT4, RPH3A, SAMSN1) trended toward higher expression in patients versus controls, and interferon-stimulated genes (ISG15, RSAD2, IFI44L) were more elevated in M2 than in M1. Conclusions: Taken together, these findings suggest that factors beyond genetics—whether epigenetic, environmental, or otherwise—may play a meaningful role in shaping how GD manifests differently even between individuals with identical DNA. Although the data are preliminary, they point to transcriptomic profiling, paired with targeted validation, as a useful starting point for building hypotheses about why this disease looks so different from one patient to the next, even when the underlying mutation is the same.

  • Open Access

    Expert opinion on clinical presentation, diagnosis and treatment of infantile onset pompe disease: a delphi study in Türkiye

    by Eki̇n Özsaydi Aktaşoğlu, Asli İnCi̇, Ridvan Murat Öktem, Gürsel Bi̇bEroğlu, İlYas Okur, Fati̇h Süheyl Ezgü, Fi̇lİz Başak Cengi̇z Ergi̇n, Abdurrahman Akgün, Nur Arslan, Hali̇l İbRahi̇m Aydin, et al.

    Background/aim: Pompe disease (acid maltase deficiency, glycogen storage disease type II, OMIM #606800) is an autosomal recessive disorder characterized by lysosomal acid-α-glucosidase deficiency. The infantile-onset type of the disease is mainly characterized by cardiomegaly, hypotonia, and a high mortality rate. This study aimed to create a national consensus about infantile-onset Pompe disease (IOPD) to raise awareness among clinicians and standardize diagnosis and treatment approaches in Türkiye. Materials and methods: The Gazi University Division of Metabolic Diseases and Nutrition developed this expert opinion consensus and expanded it to include metabolism specialists across Türkiye. A systematic literature review was performed, and the Delphi method was used to evaluate the results. Results: Seventeen conclusive questions were produced about clinical presentation, diagnosis, and treatment, and 14 reached a consensus. Consensus was reached that general hypotonia is one of the most important findings, and agreement was also achieved on the starting dose of treatment for presymptomatic patients. The contributors agreed that gene therapy is a good treatment option for IOPD in the future. Conclusion: The topics related to this consensus will help physicians in Türkiye and elsewhere with high incidence rates of IOPD,especially regarding diagnosis and treatment decisions.


  • MİTOKONDRİYAL HASTALIK NEDENİYLE TETKİK EDİLEN HASTALARDA M.16189T>C DEĞİŞİKLİĞİNİN METABOLİK SENDROM AÇISINDAN İNCELENMESİ

    by Aslı İNCİ, Filiz Başak CENGİZ ERGİN, İlyas Okur, Gürsel Bi̇beroğlu, Leyla Tümer, Fatih Süheyl Ezgü

    AMAÇ: Metabolik sendrom, obezite, yüksek düzeyde düşük yoğunluklu kolesterol düzeyi (LDL), trigliserit düzeyi (TG) ve insuline duyarlılık ile karakterize olan günümüzde sıklığı giderek artan bir bozukluktur. Metabolik sendromun etiyopatogenezinde hem genetik hem de çevresel nedenlerin rol oynadığı bilinmektedir. Özellikle mitokondriyal DNA’da oluşan m.16189T>C değişikliğinin bu hastalıkla ilişkili olduğu gösterilmiştir. Bu çalışmada mitokondriyal hastalık şüphesi ile başvuran hastalarda saptanan m.16189T>C değişikliğinin klinik ve laboratuvar bulgularının incelenmesi amaçlanmıştır.GEREÇ VE YÖNTEM: Kliniğimize 2019 - 2020 yılları arasında mitokondriyal hastalık şüphesi ile gelen hastalardan m.16189T>C değişikliği olan hastalar çalışmaya alınmıştır. Hastaların klinik ve laboratuvar bulguları mitokondriyal hastalık şüphesi taşıması nedeniyle periferik kandan mitokondriyal DNA izolasyonu yapılmıştır. Yeni nesil DNA dizileme ile tüm mitokondriyal genom DNA dizi analizi yapılarak m.16189T>C değişikliği olan hastalar saptanarak çalışmaya dahil edilmiştir. Bu hastaların klinik ve laboratuvar bulguları metabolik sendrom açısından incelenmiştir.BULGULAR: 1 yıllık süre içinde 55 hastanın 11’inde mitokondriyal genom analizinde m.16189T>C değişikliği saptanmıştır (%20). Fizik muayene bulgularında, hiçbir hastada fazla tartı ve obezite saptanmamıştır. Hastaların glukoz, LDL ve trigliserit düzeyleri normal aralıkta bulunmuştur.SONUÇ: Hasta grubumuzda oldukça yüksek oranda saptanan bu değişikliğin metabolik sendrom ile ilişkisi gösterilememiş ve polimorfizm olarak değerlendirilmiştir. Ancak mitokondriyal hastalık şüphesi ile gelen bu hastaların kullandığı ilaçların, beslenme şekillerinin ve hastalığın patofizyolojisinin bu metabolik sendromu etkileyen çevresel faktörler olabileceği ön görülebilir.

  • Open Access

    A Turkish case of incontinentia pigmenti with a deletion mutation at Inhibitor of kappa B kinase gamma gene

    by Filiz Başak Cengiz Ergin, Mustafa Tekin, Meltem Güneş, Begüm Güneş, Şahika Baysun, Nejat Akar

    Background: Incontinentia pigmenti (IP) is a rare X-linked dominant disorder affecting the skin and other ectodermal tissues that is caused by a mutation of the IKBKG/NEMO gene. Case presentation: We describe a Turkish family with IP. Sanger sequencing was performed in our patient with IP, and we identified DNA variant c.172_173delAA (p.Asn58SerfsTer79) in IKBKG. We found the same mutation in the patient's mother and grandmother. Conclusion: Our report expands the mutation spectrum in this disorder and provides valuable information on the importance of the IKBKG. Our study shows that confirmation of the mutation analysis of IP in the suspected cases is necessary for future planning pregnancies.


  • The Effect of m.3010G> A Variant on Cyclic Vomiting Syndrome in Turkish Population

    by Filiz Başak CENGİZ ERGİN, Aslı İNCİ, İlyas Okur, Gürsel Bi̇beroğlu, Leyla Tümer, Fatih Süheyl Ezgü

    Giriş ve Amaç: Siklik kusma sendromu (SKS) sık görülen gastrointestinal fonksiyonel bir düzensizliktir. Gastrointestinal fonksiyonel düzensizliklerin mitokondriyal polimorfizmlerle ilişkili olduğu gösterilmiştir. Bu çalışmada, m.3010G>A değişikliğini taşıyan hastalarda klinik bulguların incelenmesi amaçlanmıştır. Gereç ve Yöntemler: Kliniğimize mitokondriyal hastalık şüphesi ile gelen 55 hastadan, periferik kandan mitokondriyal DNA izolasyonu yapılmıştır. Yeni nesil DNA dizileme ile tüm mitokondriyal genom DNA dizi analizi yapılarak m.3010G>A değişikliği olan hastalar saptanmıştır. Bu hastalarda klinik bulgular incelenmiştir. Bulgular: Toplam 55 hastada yapılan mitokondriyal genom analizinde altı farklı hastada m.3010G>A değişikliği saptanmıştır. m.3010G>A değişikliği saptanan bu hasta grubunda SKS ile ilgili klinik bulgular saptanmamıştır. Sonuç: Daha önce yapılan çalışmalarda m.3010G>A değişikliğinin SKS ile ilişkili olabileceği gösterilmiş olsa da bizim çalışmamızda katılan hastalarda bu bulgular bulunmamaktadır. Yine de SKS’nin ileri yaşlarda da ortaya çıkabileceği göz önünde bulundurulmalı ve yakın takip edilmelidir.